Solara Active Pharma Sciences informs about press release

07 Aug 2023 Evaluate

Solara Active Pharma Sciences has informed that the company (Solara) has successfully completed the inspection carried out by the US Food and Drug Administration (US FDA or Agency) at its Cuddalore facility (Tamil Nadu). The Agency, with its designated investigators, inspected the Cuddalore facility between July 31, 2023 – August 04, 2023. The inspection established that the facility is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from the Agency. With this successful inspection outcome, the current inspection classification of Cuddalore site shall be reinstated to NAI (No Action Indicated). The Cuddalore API site is a multi-product facility, caters wide range of APIs to various regulated markets across the globe, including U.S., Europe, Japan and other markets. In this regard, the company has attached a press release.

The above information is a part of company’s filings submitted to BSE.

Solara Active Pharma Share Price

686.95 -33.60 (-4.66%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.